Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $20.50.

ADPT has been the subject of several recent analyst reports. TD Cowen lifted their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Morgan Stanley reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th.

Insiders Place Their Bets

In other news, insider Harlan S. Robins sold 386,240 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total value of $8,501,142.40. Following the completion of the transaction, the insider owned 1,019,658 shares in the company, valued at $22,442,672.58. The trade was a 27.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 30,941 shares of the company’s stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $14.66, for a total value of $453,595.06. Following the transaction, the chief operating officer directly owned 395,146 shares in the company, valued at approximately $5,792,840.36. The trade was a 7.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 977,725 shares of company stock worth $19,352,587 over the last three months. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 1492 Capital Management LLC purchased a new stake in Adaptive Biotechnologies during the fourth quarter valued at $1,484,000. Jupiter Asset Management Ltd. lifted its holdings in Adaptive Biotechnologies by 33.8% in the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after acquiring an additional 91,683 shares during the period. Rhenman & Partners Asset Management AB boosted its position in Adaptive Biotechnologies by 22.2% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after purchasing an additional 110,000 shares during the last quarter. UBS Group AG boosted its position in Adaptive Biotechnologies by 101.6% in the fourth quarter. UBS Group AG now owns 511,927 shares of the company’s stock worth $8,314,000 after purchasing an additional 257,947 shares during the last quarter. Finally, Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $65,942,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $20.16 on Friday. Adaptive Biotechnologies has a 1 year low of $9.96 and a 1 year high of $22.80. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -61.09 and a beta of 2.07. The company has a 50-day moving average of $16.50 and a 200 day moving average of $15.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the previous year, the firm posted ($0.20) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis. On average, equities analysts anticipate that Adaptive Biotechnologies will post -0.47 EPS for the current year.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Negative Sentiment: Harlan Robins sold 386,240 shares of Adaptive Biotechnologies, a transaction worth about $8.5 million, which is the most notable insider sale and may signal caution to investors. Article Title
• Negative Sentiment: Susan Bobulsky sold 487 shares, adding to a pattern of insider selling at Adaptive Biotechnologies. Article Title
• Negative Sentiment: Francis Lo sold 44,838 shares and separately sold another 51,004 shares, reinforcing the recent insider selling trend in ADPT. Article Title
• Neutral Sentiment: Recent filings note that these sales were made under pre-arranged 10b5-1 trading plans, which can reduce the significance of the transactions compared with discretionary selling.
• Positive Sentiment: Adaptive Biotechnologies previously posted better-than-expected quarterly results, including revenue growth of 35.1% year over year and EPS that beat estimates, which may help limit downside pressure.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.